-+ 0.00%
-+ 0.00%
-+ 0.00%

B. Riley Securities Reiterates Buy on Cue Biopharma, Lowers Price Target to $25

Benzinga·11/18/2026 14:36:02
B. Riley Securities analyst Mayank Mamtani reiterates Cue Biopharma (NASDAQ:CUE) with a Buy and lowers the price target from $83 to $25.